Kyung Chul Yoon, Sanghee Song, Eun‐Kyoung Jwa, Sanghoon Lee, Jong Man Kim, Ok‐kyoung Kim, Suk Kyun Hong, Nam‐Joon Yi, Kwang‐Woong Lee, Myoung Soo Kim, Shin Hwang, Kyung‐Suk Suh, Suk‐Koo Lee – 10 May 2018 – Split‐liver transplantation (SLT) should be cautiously considered because the right trisection (RTS) graft can be a marginal graft in adult recipients. Herein, we analyzed the outcomes of RTS‐SLT in Korea, where >75% of adult liver transplantations are performed with living donor liver transplantation.

Peng Sun, Yue‐Xin Lu, Daqing Cheng, Kuo Zhang, Jilin Zheng, Yupeng Liu, Xiaozhan Wang, Yu‐Feng Yuan, Yi‐Da Tang – 9 May 2018 – Sterile inflammation is an essential factor causing hepatic ischemia/reperfusion (I/R) injury. As a critical regulator of inflammation, the role of monocyte chemoattractant protein‐induced protein 1 (MCPIP1) in hepatic I/R injury remains undetermined. In this study, we discovered that MCPIP1 downregulation was associated with hepatic I/R injury in liver transplant patients and a mouse model.

Kristina Behnke, Yuan Zhuang, Haifeng C. Xu, Balamurugan Sundaram, Maria Reich, Prashant V. Shinde, Jun Huang, Nastaran Fazel Modares, Alexei V. Tumanov, Robin Polz, Jürgen Scheller, Carl F. Ware, Klaus Pfeffer, Verena Keitel, Dieter Häussinger, Aleksandra A. Pandyra, Karl S. Lang, Philipp A. Lang – 9 May 2018 – The liver has an extraordinary capacity to regenerate through activation of key molecular pathways. However, central regulators controlling liver regeneration remain insufficiently studied.

Ahmer M. Hameed, Jerome M. Laurence, Vincent W. T. Lam, Henry C. Pleass, Wayne J. Hawthorne – 9 May 2018

Kazi Abdus Salam, Richard Y. Wang, Teresa Grandinetti, Valeria Giorgi, Harvey J. Alter, Robert D. Allison – 9 May 2018 – Erythrocytes bind circulating immune complexes (ICs) and facilitate IC clearance from the circulation. Chronic hepatitis C virus (HCV) infection is associated with IC‐related disorders. In this study, we investigated the kinetics and mechanism of HCV and HCV‐IC binding to and dissociation from erythrocytes. Cell culture‐produced HCV was mixed with erythrocytes from healthy blood donors, and erythrocyte‐associated virus particles were quantified.

Morgan Preziosi, Satdarshan P. Monga – 9 May 2018

John E. Eaton, Mette Vesterhus, Bryan M. McCauley, Elizabeth J. Atkinson, Erik M. Schlicht, Brian D. Juran, Andrea A. Gossard, Nicholas F. LaRusso, Gregory J. Gores, Tom H. Karlsen, Konstantinos N. Lazaridis – 9 May 2018 – Improved methods are needed to risk stratify and predict outcomes in patients with primary sclerosing cholangitis (PSC). Therefore, we sought to derive and validate a prediction model and compare its performance to existing surrogate markers.

Emily K. Butler, Jeffrey Gersch, Anne McNamara, Ka‐Cheung Luk, Vera Holzmayer, Maria de Medina, Eugene Schiff, Mary Kuhns, Gavin A. Cloherty – 7 May 2018 – Treatment of chronic hepatitis B (CHB) patients with nucleos(t)ide analogs (NAs) suppresses hepatitis B virus (HBV) DNA synthesis but does not affect synthesis of HBV pregenomic RNA (pgRNA). Hepatitis B virus pgRNA is detectable in the serum during NA treatment and has been proposed as a marker of HBV covalently closed circular DNA activity within the infected hepatocyte.

Yuanjie Pang, Christiana Kartsonaki, Iain Turnbull, Yu Guo, Robert Clarke, Yiping Chen, Fiona Bragg, Ling Yang, Zheng Bian, Iona Y. Millwood, Juanzhi Hao, Xianyong Han, Yajing Zang, Junshi Chen, Liming Li, Michael V. Holmes, Zhengming Chen – 7 May 2018 – The prevalence of diabetes is increasing rapidly in China. However, evidence is limited about its effects on chronic liver diseases and liver cancer.

Nora Winkler, Felix Strübing, Wolfgang Groß, Walter Mier, Eduard Ryschich – 7 May 2018 – The systemic drug circulation represents a source of adverse effects during tumor targeting. We studied the binding efficacy of endothelium‐specific antibodies after a very short contact with an antigen target, along with assessing the intravascular capture and targeting potential of these antibodies after locoregional injection. Fast‐binding anti–CD 146 (clone ME‐9F1) and anti‐CD31 (clone 390) antibodies were selected based on histological analysis of their binding activity.